Diabetes Treatment and Management
Diabetes Treatment and Management is a research topic within Endocrinology, Diabetes and Metabolism. Science Explorer counts 46k research works in it since 1950. 22.9% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the management of diabetes mellitus, with a particular emphasis on cardiovascular outcomes, glucose control, and the use of incretin hormones, SGLT2 inhibitors, and dipeptidyl peptidase-4 inhibitors. It also covers topics such as heart failure, glycemic control, insulin therapy, and clinical guidelines for the treatment of type 2 diabetes.
- Type 2 Diabetes
- Cardiovascular Outcomes
- Glucose Control
- Incretin Hormones
- SGLT2 Inhibitors
- Dipeptidyl Peptidase-4 Inhibitors
- Heart Failure
- Glycemic Control
- Insulin Therapy
- Clinical Guidelines
- Research works
- 46k fractional, since 1950
- In the world top 10%
- 11k per year above
- Top-10% rate
- 22.9% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +34% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Diabetes Treatment and Management research?
By volume, the United States and China publish the most (2.8k and 1.4k works in 2022–2025).
By volume, 2022–2025
- 1 United States 2.8k works
- 2 China 1.4k works
- 3 India 620 works
- 4 United Kingdom 562 works
- 5 Japan 501 works
- 6 Italy 441 works
- 7 Germany 420 works
- 8 Canada 307 works
- 9 Spain 295 works
- 10 South Korea 278 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Diabetes Treatment and Management research?
By volume in 2022–2025, Eli Lilly (United States) publishes the most Diabetes Treatment and Management research, followed by Harvard University and Brigham and Women's Hospital.
By volume, 2022–2025
- 1 Eli Lilly (United States)United States 46 works
- 2 Harvard UniversityUnited States 46 works
- 3 Brigham and Women's HospitalUnited States 43 works
- 4 University of CopenhagenDenmark 39 works
- 5 University of North Carolina at Chapel HillUnited States 37 works
- 6 University of TorontoCanada 36 works
- 7 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 34 works
- 8 Novo Nordisk (Denmark)Denmark 34 works
- 9 Yale UniversityUnited States 33 works
- 10 Johns Hopkins UniversityUnited States 31 works
Who are the leading researchers in Diabetes Treatment and Management?
The most-cited researchers publishing on Diabetes Treatment and Management include Giuseppe Remuzzi, Amirhossein Sahebkar and Josef Coresh.
- 1 Giuseppe Remuzzi Italy 8.1k citations
- 2 Amirhossein Sahebkar Iran 5.6k citations
- 3 Josef Coresh United States 5.3k citations
- 4 Winfried März Germany 5.2k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Diabetes Treatment and Management research done?
The largest centres of Diabetes Treatment and Management research in 2022–2025 are Beijing (China), Seoul (South Korea), London (United Kingdom) and Copenhagen (Denmark). Among places with at least 20 works in it, it is an unusually large share of all research in Charlottenlund.
Largest cities, 2022–2025
Where it is the local speciality
- CharlottenlundDK · 23.1 works72×
Location quotient: how much more of its research is in Diabetes Treatment and Management than the world average.
Where is the best place to study Diabetes Treatment and Management?
Among universities, judged by research, University of Copenhagen, Harvard University and National and Kapodistrian University of Athens score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | University of CopenhagenDenmark | 64.6 | 41.1% | 5.3× | 39 | +30.9% |
| 2 | Harvard UniversityUnited States | 64.2 | 46.2% | 3.3× | 46 | +50.5% |
| 3 | National and Kapodistrian University of AthensGreece | 58.4 | 41.8% | 4.1× | 22 | +115.7% |
| 4 | University of Campania "Luigi Vanvitelli"Italy | 57.8 | 49.7% | 5.9× | 13 | +68.6% |
| 5 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 56.3 | 34.0% | 3.3× | 34 | +141.4% |
| 6 | Karolinska InstitutetSweden | 53.9 | 33.9% | 4.6× | 22 | +33.7% |
| 7 | University of TorontoCanada | 52.9 | 36.9% | 2.3× | 36 | +40.6% |
| 8 | Kawasaki Medical SchoolJapan | 52.7 | 32.7% | 22.9× | 9 | +79.4% |
| 9 | Dow University of Health SciencesPakistan | 52.4 | 18.0% | 12.9× | 17 | +21.8% |
| 10 | Imperial College LondonUnited Kingdom | 52.3 | 42.6% | 2.5× | 25 | +12.1% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Diabetes Treatment and Management research growing?
Output in 2018–2022 was 34% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Diabetes Treatment and Management.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.